342 related articles for article (PubMed ID: 36263616)
1. Roles of DNA damage repair and precise targeted therapy in renal cancer (Review).
Lai Y; Li Z; Lu Z; Zheng H; Chen C; Liu C; Yang Y; Tang F; He Z
Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36263616
[TBL] [Abstract][Full Text] [Related]
2. PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Chabanon RM; Morel D; Eychenne T; Colmet-Daage L; Bajrami I; Dorvault N; Garrido M; Meisenberg C; Lamb A; Ngo C; Hopkins SR; Roumeliotis TI; Jouny S; Hénon C; Kawai-Kawachi A; Astier C; Konde A; Del Nery E; Massard C; Pettitt SJ; Margueron R; Choudhary JS; Almouzni G; Soria JC; Deutsch E; Downs JA; Lord CJ; Postel-Vinay S
Cancer Res; 2021 Jun; 81(11):2888-2902. PubMed ID: 33888468
[TBL] [Abstract][Full Text] [Related]
3. Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.
Okazaki A; Gameiro PA; Christodoulou D; Laviollette L; Schneider M; Chaves F; Stemmer-Rachamimov A; Yazinski SA; Lee R; Stephanopoulos G; Zou L; Iliopoulos O
J Clin Invest; 2017 May; 127(5):1631-1645. PubMed ID: 28346230
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in cancer therapy using PARP inhibitors.
Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
[TBL] [Abstract][Full Text] [Related]
5. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
[TBL] [Abstract][Full Text] [Related]
6. Targeting DNA damage response pathways in cancer.
Groelly FJ; Fawkes M; Dagg RA; Blackford AN; Tarsounas M
Nat Rev Cancer; 2023 Feb; 23(2):78-94. PubMed ID: 36471053
[TBL] [Abstract][Full Text] [Related]
7. Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy.
Ueno D; Vasquez JC; Sule A; Liang J; van Doorn J; Sundaram R; Friedman S; Caliliw R; Ohtake S; Bao X; Li J; Ye H; Boyd K; Huang RR; Dodson J; Boutros P; Bindra RS; Shuch B
Oncotarget; 2022; 13():1054-1067. PubMed ID: 36128328
[TBL] [Abstract][Full Text] [Related]
8. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
10. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
11. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
13. Biomarker-Guided Development of DNA Repair Inhibitors.
Cleary JM; Aguirre AJ; Shapiro GI; D'Andrea AD
Mol Cell; 2020 Jun; 78(6):1070-1085. PubMed ID: 32459988
[TBL] [Abstract][Full Text] [Related]
14. Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?
Demidova EV; Ghatalia P; Arora S
Eur Urol; 2022 Feb; 81(2):149-150. PubMed ID: 34753637
[No Abstract] [Full Text] [Related]
15. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
17. Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
Zhang Q; Xu Y; Zhang Z; Li J; Xia Q; Chen Y
Gene; 2021 Feb; 769():145243. PubMed ID: 33069804
[TBL] [Abstract][Full Text] [Related]
18. DNA Damage Repair Inhibitor for Breast Cancer Treatment.
Min A; Lee KH; Im SA
Adv Exp Med Biol; 2021; 1187():159-179. PubMed ID: 33983578
[TBL] [Abstract][Full Text] [Related]
19. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
Voutsadakis IA; Stravodimou A
Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
[TBL] [Abstract][Full Text] [Related]
20. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]